Cediranib
Lung Carcinoid Tumor
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lung Carcinoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus National Cancer Institute (NCI) | Phase 2 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 2 | B |
gw786034 National Cancer Institute (NCI) | Phase 2 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 2 | B |
Octreotide Pamoate Roswell Park Cancer Institute | Phase 1 | CCC |
Cixutumumab National Cancer Institute (NCI) | Phase 1 | CC |
Trebananib National Cancer Institute (NCI) | Phase 1 | CC |
Everolimus National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →